Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.39 |
| ▸ | TUBB | P07437 | 4/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | DBH | P09172 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17170044 | 0.82 | RHEB (0.38) | RHEB | |
| SCHEMBL12352383 | 0.77 | RHEB (0.40) | RHEBKDM4EPTPN1ALDH1A1 | |
| SCHEMBL18054255 | 0.76 | NOTUM (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18052988 | 0.75 | PTGER4 (0.35) | TUBB1CYP19A1CACNA1HFFAR4 | |
| SCHEMBL16065343 | 0.75 | RHEB (0.39) | RHEBKDM4EALDH1A1 | |
| SCHEMBL17452807 | 0.72 | CYP19A1 (0.39) | CYP19A1 | |
| SCHEMBL10257300 | 0.72 | RHEB (0.37) | RHEBKDM4EALDH1A1 | |
| SCHEMBL18054201 | 0.72 | CYP19A1 (0.37) | CYP19A1CACNA1HFFAR4 | |
| SCHEMBL6000255 | 0.71 | RHEB (0.46) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL28909272 | 0.71 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261637-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3261638-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9550760-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIOSCIENCE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016137506-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2016-01-21 | — | — | US | disclosed |
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | RHEB 751/4885TUBB4A 1127/4885TUBB 590/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | RHEB 4267/4885TUBB4A 1647/4885TUBB 1362/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | RHEB 4267/4885TUBB4A 1647/4885TUBB 1362/4885 |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | RHEB 821/4885TUBB4A 1196/4885TUBB 660/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | RHEB 4267/4885TUBB4A 1647/4885TUBB 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.